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Abstract: Homocysteine (HCy) is a sulphur-containing amino acid that correlates with several
maladaptive health conditions, including an enhanced risk of cardiovascular and neurodegenerative
diseases. Detection of HCy and its potentially pathogenic metabolites are studied here for the first
time, to the first of our knowledge, using Raman spectroscopy. This study shows that different
HCy metabolites have distinct Raman spectra and that the limits of detection reach the sub-mM
level for these compounds. This investigation paves the way for photonics–based approaches for
detection of HCy–related fluids as predictive biomarkers of disease in blood, which would assist
in early intervention for improved clinical outcomes.
Published by The Optical Society under the terms of the Creative Commons Attribution 4.0 License. Further
distribution of this work must maintain attribution to the author(s) and the published article’s title, journal
citation, and DOI.
1. Introduction
Homocysteine (HCy) is a sulphur–containing amino acid produced as a by–product of the
S–adenosyl methionine cycle. Under normal circumstances, generated HCy is either recycled
back to form methionine via a folate–dependent pathway, or broken down for renal excretion
following condensation with serine to form cystothionine [1]. As accepted widely, normal plasma
HCy levels are 5-15 µM. Elevated circulating levels of HCy (>15 µM) have been prospectively
linked to an enhanced risk of cardiovascular and neurodegenerative disease [2]. Furthermore, the
metabolic disorder, homocysteinuria, occurs in individuals with homozygous null mutations in
genes encoding either methyl tetrafolate reductase or cystathionine β–synthase. These patients
have vastly elevated HCy levels in the range of 100–500µM [3] and present with a spectrum
of symptoms including skeletal abnormalities [4], cardiovascular disease, ophthalmological
abnormalities and neuropsychiatric disorders [5]. Early intervention with a low-methionine diet
and high dose folate and B vitamin therapy can halt, and indeed reverse, a number of these
symptoms.
In addition to HCy per se, its metabolites have been observed to have deleterious effects on
health and wellbeing. Homocysteine thiolactone (HT) has been linked to deficits in vascular
function [6], and the activity of homocysteine thiolactonase, the enzyme that hydrolyses HT
to HCy, for breakdown and excretion, is reduced in Alzheimer’s Disease patients [7] linking
increased HT levels to neurodegeneration. Administration of an oxidised metabolite of HCy,
homocysteic acid (HA) to rodents induces increased arterial pressure and heart rate [8] and
HA also causes Aβ1-42 accumulation in neurons linking it to the pathogenesis of Alzheimer’s
Disease [9]. Together these findings imply that not only HCy, but also substances that are
known metabolic fates of this amino acid, are linked to the pathogenesis of cardiovascular and
neurodegenerative diseases.
To date the relative amounts of HCy and its potentially pathogenic metabolites have not been
investigated in either patient samples or under laboratory conditions. One of the reasons for
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this lack of data rests with the difficulty in accurately discriminating between and detecting
these substances. HCy levels within blood can change markedly and rapidly following sample
collection. As HCy is released from cellular components, levels increase at the rate of 10% per
hour following blood sampling and thus rapid separation of blood cells from plasma and serum
is required [10]. Following separation, plasma HCy levels are stable and a variety of techniques
can be used for determination of levels including mass spectroscopy [11] and enzymatic assays
[12]. HT can be measured using HPLC or GS/MS [13] although routine blood sampling for this
and HA is not currently available. HA can be measured by liquid mass spectrometry [14] or
GS/MS [15].
As the potential for HCy metabolites to mediate HCy–linked neurotoxicity and cardiovascular
dysfunction emerges, the need to simultaneously measure HCy, HT and HA in a single sample
presents itself as a key challenge. To achieve this goal, it is necessary to develop an assay where
the three metabolites can be identified and measured. In this paper, we explore the powerful
label-free approach of Raman spectroscopy to address this question. Raman analysis generates a
chemical fingerprint of a sample, and has previously been used successfully on cells [16,17],
bacteria [18–20] and tissue [21].
Importantly, to date, there are very few studies of Raman analysis on these important
metabolites in the literature [22] while a few others rely on alternative techniques, such as
terahertz spectroscopy and near-infrared fluorescence spectroscopy [23–25]. Here, we address
this and use Raman analysis to acquire unique spectra from each of these metabolites, monitor
metabolite concentrations and set limits on detection. In particular, we use a recently developed
variant of Raman analysis, wavelength modulated Raman spectroscopy (WMRS) [16,17,26],
and compare that with a standard Raman approach. WMRS allows us to remove any obscuring
background fluorescence without the need to use any polynomial fitting. This is mainly based
on the premise that the background fluorescence does not change when the excitation laser
wavelength is tuned over a small range of 1.5 nanometres, while the Raman peaks do change.
The use of WMRS is shown to lead to an increased sensitivity for detection of HCy and its
pathogenic metabolites. Our work will ultimately lead to label-free optical analysis for these
important metabolites.
2. Methods
2.1. Preparation of homocysteine metabolite solutions
All chemical samples were obtained from Sigma Aldrich UK and exist as a 50:50 ratio of the
D– and L– stereoisomers. Aliquots of each chemical were weighed and stored at −20 ◦C with
desiccant prior to experiments. Immediately before performing Raman spectroscopy, HCy was
prepared as a 200 mM stock in 0.15 M NaCl solution which does not have distinctive Raman
peaks between 500 cm−1 and 2000 cm−1 [27,28]. Saline with a physiological concentration of
NaCl was used to dissolve HCy as this compound exhibits a salting-in behavior in physiological
fluids allowing preparation of a higher concentration stock than could be obtained in water alone
[29]. This stock was then further diluted in 0.15 M NaCl to give experimental samples at 100
mM, 80 mM, 50 mM and 20 mM. Both HT and HA were prepared as a 200 mM stock in dH2O,
and further diluted to give 100 mM, 80 mM, 50 mM, 20 mM, 10 mM and 5 mM samples. A
volume of 20 µL sample solution was loaded into a well formed by one thick quartz slide (1 mm
thickness), one thin quartz slide (∼ 170µm thickness) and a vinyl spacer with a central hole.
2.2. Raman spectroscopy
The standard and wavelength modulated Raman spectroscopy was performed with a wavelength
tunable Ti:Sapphire laser (Spectra-Physics 3900s, 1 W@785 nm) to excite Raman photons
which were collected by a monochromator (Shamrock SR-303i, Andor Technology) and a
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thermoelectrically cooled CCD camera (Newton, Andor Technology) [16]. An oil immersion
objective (Nikon, NA0.9/50X) focused the laser onto the sample, delivering a power of 150
mW to the sample solution. We verified that this laser dosage did not cause any damage by
continuously acquiring Raman spectra from sample solutions for half an hour, upon which no
change was found in all acquired spectra.
For the system operating in standard Raman mode, we acquired at least five spectra from each
sample solution by setting the tunable Ti:Sapphire laser to a fixed wavelength of 785 nm. An
acquisition time of 28 s was used to record a single spectrum from differing concentrations of
HCy, HT and HA in solution.
Wavelength modulated Raman spectra from the sample solution were obtained with exactly
the same system with only a slight modification of procedure and laser operation. Five Raman
spectra were recorded from the sample solution at different excitation wavelengths for a total
modulation range of ∆λ = 1nm. We note that a longer overall acquisition time is needed for
WMRS as the same acquisition time of 28s was used for each individual spectrum. Principal
component analysis (PCA) was used to analyze these five spectra, with each wavelength step as a
parameter, to produce a modulated Raman spectrum with essentially all fluorescence background
being suppressed [16,17]. As a result, all Raman peaks are indicated by the zero crossing points
in the resulting modulated Raman spectrum.
2.3. Data analysis
Raman spectra in the region of 600 cm−1 to 1800 cm−1 were used for subsequent analysis. Since
the intensity of the Raman peak varies depending on the concentration of sample solution, we
monitored the intensity of the most significant Raman peak (670 cm−1, 1050 cm−1 and 690 cm−1
in HCy, HA and HT Raman spectra respectively). For the Standard Raman spectrum, we directly
calculate the peak intensity from the baseline at the peak position. For the wavelength modulated
Raman spectrum, the peak intensity was calculated from the peak–to–valley value at the zero
crossing point.
3. Results
HCy, HA and HT show unique Raman spectra
The most critical step in the study was to determine whether the three metabolites had unique
Raman spectra that could be readily distinguished from one another. Figure 1 shows standard
Raman spectra and WMR spectra from HCy, HA and HT solutions. Distinct Raman fingerprints
can be clearly observed at the peaks in standard Raman spectra or at the zero crossing points
in WMRS. Different Raman fingerprints are shown for HCy (Fig. 1(a) and (b)), HA (Fig. 1(c)
and (d)) and HT (Fig. 1(e) and (f)). Typical Raman peaks from our measurements are shown in
Table 1.
Table 1. Typical Raman peaks in HCy, HA
and HT solutions. A characteristic Raman
peak for each solution were indicated by
the bold-font number.
Typical Raman peak positions (cm−1)
HCy 670, 756, 865, 1086, 1360, 1420, 1448
HA 820, 1050, 1200, 1430
HT 690, 745, 982, 1190, 1395, 1465
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Fig. 1. Standard Raman spectra (a, c, e) and wavelength modulated Raman spectra (b, d, f)
of HCy solution at a concentration of 0.2 M, HA solution with a concentration of 0.1 M and
HT solution at a concentration of 0.1 M. Arrows indicate the most significant Raman peaks
at 670 cm−1, 1050 cm−1 and 690 cm−1 for HCy, HA and HT respectively. The dashed line
in (b), (d), and (f) shows the zero intensity in wavelength modulated Raman spectra.
3.1. Raman peak intensity correlates with the concentrations of HCy, HA or HT in
solution
As would be expected, our data demonstrate that the intensity of Raman peaks varies depending
on the concentration of solution. Here we focus on the most significant Raman peak of spectra of
HCy, HA or HT solutions in order to monitor the peak intensity relative to the concentration of
sample solutions and set a limit of detection for the current system. From the spectrum region of
600–1800 cm−1, three most significant Raman peaks at 670 cm−1, 1050 cm−1, and 690 cm−1
were selected as characteristic Raman peaks for HCy, HA and HT solutions respectively.
Figure 2 shows the relationship between these characteristic Raman peak intensities and the
concentrations of the metabolites in solution. The linearity between the Raman peak intensity
and the concentration can be clearly observed for all three compounds investigated. Clearly,
WMRS shows an improvement in measuring these Raman peaks at different concentrations.
We also evaluated the signal to noise ratio (SNR) for each measurement by taking the ratio
of measured characteristic Raman peak intensity value to the standard deviation of the Raman
free spectral region (noise region) between 1925 cm−1 and 1985 cm−1. For the standard Raman
spectra, we take the first differential and then evaluate the SNR in the same way. In Fig. 3 we see
that the SNR has been enhanced by a factor of two for the WMR spectra due to the suppression
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Fig. 2. Raman peak intensities as a function of concentrations for (a) HCy, (b) HA and
(c) HT solution with both axes on the log scale. Blue stars show the peak intensities of
wavelength modulation Raman spectra and red circles show the peak intensities of standard
Raman spectra at 670 cm−1, 1050 cm−1 and 690 cm−1. Dashed lines shows the linear fits
from the experimental data.
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of the fluorescence background. The sensitivity of the concentration prediction ability can be
defined as the slope (β) of these linear fitted curves, which also show an enhancement by a factor
of two for the WMR spectra. Therefore, our experimental results indicate that WMRS improves
the prediction of concentration for these key metabolites as a result of the fluorescent background
suppression associated with the technique. Furthermore, the theoretical detection limit can be
estimated by 1/β, which is the concentration when SNR is approaching to 1. In our study, the
theoretical detection limits for HCy, HA and HT using WMRS are 3.704, 0.719 and 0.724 mM
respectively.
Fig. 3. Comparison of signal to noise ratio between standard Raman spectra and WMR
spectra obtained from (a) HCy, (b) HA, and (c) HT solution. Dashed lines show the linear
fits from the experimental data and the slopes of the fitted lines are indicated by the value of
β.
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4. Conclusions and discussions
In this study, our primary objective was to determine whether key metabolites that have been
shown to link HCy dysregulation to cardiovascular and neurodegenerative disease [2] have
unique Raman spectra. We have confirmed this by recording unique Raman fingerprints for each
metabolite suggesting that Raman spectroscopy offers the potential to rapidly and accurately detect
HCy, HA and HT in solution. Furthermore, we have demonstrated a concentration-dependent
change in the intensity of the major peak for each metabolite indicating that we can determine
the concentration as well as the presence of each of these metabolites.
We demonstrated that WMRS exhibited enhanced sensitivity in detecting these solutions when
compared to standard Raman and this is in keeping with previous studies demonstrating that
WMRS can give greater sensitivity in the detection of biological parameters. Restricted by the
laser power and the focusing lens used in our system, the low limits of detection are typically
below 4 mM for each metabolite studied. Here, those prominent Raman peaks at 670 cm−1 and
690 cm−1 from the HCy and HT are strongly related to the (C-S) stretching mode and (C-S) trans
respectively in the molecues [30]. The Raman peak at 1050 cm−1 indicates the SO3 stretching
in HA molecues [31]. As each metabolite shows a unique Raman fingerprint, it is possible to
measure the concentration of these three metabolites simultaneously in a solution. This implies
that determining the relative level of each in biological samples such as blood is possible if the
these fingerprints are not overwhelmed by those from other contents.
It has long been established that HCy is a prospective risk factor for the development of
cardiovascular and neurodegenerative conditions, having been identified as increasing future
risk of heart disease in the 1970s [32] and of Alzheimer’s Disease in 2002 [33]. Despite these
findings, vitamin-based therapies to reduce HCy burden have failed to show beneficial effects
for patients on either cardiovascular [34] or cognitive parameters [35]. The reasons for this are
unclear. It is possible that the damage caused by HCy pre-dates the onset of symptoms and
therefore lowering levels after the disease process has begun offers no patient benefit. Indeed,
HCy levels are not routinely clinically measured [36] and therefore early identification of patients
who would benefit from intervention to lower HCy levels is difficult. There is emerging data
that early intervention to lower HCy prior to disease onset could be beneficial. Thus in high-risk
patients, such as those with elevated cardiovascular disease risk due to rheumatoid arthritis,
HCy-lowering therapies using folate resulted in decreased carotid intima-media thickness, an
indicator of future cardiovascular events [37]. It will be interesting to see if further longitudinal
studies provide clear evidence that this decrease in carotid intima-media thickness translates to a
verified decrease in cardiovascular events in these patients. Similarly, vitamin B supplementation
given to hyperhomocysteinemic patients (55-95 yrs) who do not show evidence of Alzheimer’s
disease, resulted in decreased HCy levels correlated to the enhanced cognitive function [38]. This
again suggests that early intervention, prior to the onset of clinically relevant cognitive decline
could be protective. Crucially all of this evidence focused on HCy alone and did not consider
HT or HA, both of which have maladaptive effects in the nervous system. It is plausible that
in studies with no patient benefit observed that HA and HT levels are not significantly altered
following B vitamin administration and that additional pharmacological interventions may be
required to significantly affect these metabolites.
In these experiments, our limit of detection is 10-fold higher than that required for use of
such Raman analysis in a physiological setting, which is smaller than 500 µM. However, with
further refinement and enhancement, for example, using a surface-enhanced Raman approach,
our method shows excellent potential to approach the physiologically meaningful range. In future,
it paves the way to rapidly monitor the levels of these important metabolites, either as a single
compound or in a mixture, in a clinical setting. Our work also paves the way for future studies
using either enhancement techniques (e.g. Surface enhanced Raman analysis) [39] performed on
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microfluidic or paper based substrates that would may ultimately lead to label free point-of-care
analysis for these compounds.
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